Emerging biomarkers and comprehensive genomic profiling for NSCLC and thyroid cancer
In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice with the illustration of patient case studies.
Features of this webinar include:
- Easy navigation by topic
- Linked access to supporting references
- Case study assessment questions
- The ability to follow along and perform specific searches within the transcript
Already registered? Log in to access the full video
About the expert contributors
Dr. Vivek Subbiah
Dr. Vivek Subbiah is currently Chief of Early-Phase Drug Developments at the Sarah Cannon Research Institute, Nashville, TN, USA.
Read more »
Dr. Alexander Drilon
Dr. Alexander Drilon is the Chief of the Early Drug Development Service and an Associate Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, New York, USA.
Read more »
Dr. Michelle Williams
Dr. Michelle D. Williams is a Professor in Anatomical Pathology and Section Chief for Head and Neck Pathology at University of Texas MD Anderson Cancer Centre, USA.
Read more »
Next-generation sequencing is a powerful tool that can identify mutations or fusions in a wide range of cancers, enabling physicians to provide targeted therapy to patients and improve outcomes. In this vodcast, Professor Andrew Beggs discusses practical aspects of this technique from the clinical viewpoint.
00:00 – Introduction from Professor Beggs
02:00 – Biopsy types for NGS
06:50 – DNA versus RNA for analysis
12:37 – Processing considerations – an NHS case study
15:30 – Integrating genomic profiling into patient care and management
22:12 – Conclusions
Already registered? Log in here to watch the vodcast
About the expert contributor
Prof. Andrew Beggs
Prof. Beggs is a Professor of Cancer Genetics & Surgery in the Institute of Cancer and Genomic Sciences, University of Birmingham and Deputy Director of the Birmingham Experimental Cancer Medicine Centre. Read more »
Financial disclosure
This content is intended only for US-based healthcare providers, and was made possible by educational funding provided by Illumina, Inc., and Eli Lilly and Company.
Disclaimer
Any information provided and opinions expressed do not necessarily reflect the views of Springer Medizin GmbH. Springer Medizin GmbH and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.
